TEK and ovarian cancer: Co-targeting of VEGFR1, -3 and Tie-2 has been associated with reduced growth of solid human ovarian cancer in mice, and furthermore, combined gene therapy using VEGFR2 and Tie-2 with chemotherapy has reduced the growth of tumors, as well as diminishing the formation of ascites in mice [31].